Agex Therapeutics Stock Beta
| AGEDelisted Stock | USD 0.74 0.01 1.37% |
AgeX Therapeutics fundamentals help investors to digest information that contributes to AgeX Therapeutics' financial success or failures. It also enables traders to predict the movement of AgeX Stock. The fundamental analysis module provides a way to measure AgeX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AgeX Therapeutics stock.
AgeX |
AgeX Therapeutics Company Beta Analysis
AgeX Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current AgeX Therapeutics Beta | 1.19 |
Most of AgeX Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AgeX Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, AgeX Therapeutics has a Beta of 1.187. This is 38.02% higher than that of the Biotechnology sector and 14.6% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
AgeX Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AgeX Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AgeX Therapeutics could also be used in its relative valuation, which is a method of valuing AgeX Therapeutics by comparing valuation metrics of similar companies.AgeX Therapeutics is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, AgeX Therapeutics will likely underperform.
AgeX Fundamentals
| Return On Asset | -0.82 | |||
| Operating Margin | (63.57) % | |||
| Current Valuation | 33.33 M | |||
| Shares Outstanding | 2.5 M | |||
| Shares Owned By Insiders | 75.73 % | |||
| Shares Owned By Institutions | 5.64 % | |||
| Number Of Shares Shorted | 4.47 K | |||
| Price To Earning | (5.95) X | |||
| Price To Book | 12.96 X | |||
| Price To Sales | 221.90 X | |||
| Revenue | 142 K | |||
| Gross Profit | 125 K | |||
| EBITDA | (9.83 M) | |||
| Net Income | (14.8 M) | |||
| Cash And Equivalents | 645 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 4.37 M | |||
| Debt To Equity | 0.75 % | |||
| Current Ratio | 0.19 X | |||
| Book Value Per Share | 5.07 X | |||
| Cash Flow From Operations | (7.8 M) | |||
| Short Ratio | 3.88 X | |||
| Earnings Per Share | (13.36) X | |||
| Beta | 1.19 | |||
| Market Capitalization | 31.51 M | |||
| Total Asset | 11.96 M | |||
| Retained Earnings | (131.01 M) | |||
| Working Capital | (5.16 M) | |||
| Current Asset | 5.06 M | |||
| Current Liabilities | 5.17 M | |||
| Z Score | -14.21 | |||
| Net Asset | 11.96 M |
About AgeX Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AgeX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AgeX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AgeX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in AgeX Stock
If you are still planning to invest in AgeX Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AgeX Therapeutics' history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |